No I meant hyper progression, pseudoprogression has been anticipated for some time... therefore it was not a true safety issue. There were questions of about trial data being potentially inacurrate in this context, but there is no sign that that would have suggested either a safety issue (which would be hyperprogression) or that they were confused enough, given survival stats, that it would have been declared futile. The futility fears are born of paranoia about regulatory agencies that I find quaint, but unrealistic from experience. This was not a replay of Dendreon, which actually did have problems with its trial, despite the groans of long’s there, and ultimately was approved. Their problem ultimately was production and that the product itself was not ready for commercialization once it was approved.